keyword
https://read.qxmd.com/read/38689663/the-effect-of-black-cohosh-extract-and-risedronate-coadministration-on-bone-health-in-an-ovariectomized-rat-model
#21
JOURNAL ARTICLE
Amy L Inselman, Elysia A Masters, Jalina N Moore, Rajiv Agarwal, Audrey Gassman, Gemma Kuijpers, Richard D Beger, Kenneth B Delclos, Sybil Swift, Luísa Camacho, Michelle M Vanlandingham, Daniel Sloper, Noriko Nakamura, Gonçalo Gamboa da Costa, Kellie Woodling, Matthew Bryant, Raul Trbojevich, Qiangen Wu, Florence McLellen, Donna Christner
Preparations of black cohosh extract are sold as dietary supplements marketed to relieve the vasomotor symptoms of menopause, and some studies suggest it may protect against postmenopausal bone loss. Postmenopausal women are also frequently prescribed bisphosphonates, such as risedronate, to prevent osteoporotic bone loss. However, the pharmacodynamic interactions between these compounds when taken together is not known. To investigate possible interactions, 6-month-old, female Sprague-Dawley rats underwent bilateral ovariectomy or sham surgery and were treated for 24 weeks with either vehicle, ethinyl estradiol, risedronate, black cohosh extract or coadministration of risedronate and black cohosh extract, at low or high doses...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38688428/exploring-paediatric-oral-suspension-development-challenges-requirements-and-formulation-advancements
#22
REVIEW
Sachin S Gaikwad, Javier O Morales, Narayan B Lande, Johanna Catalán-Figueroa, Umesh D Laddha, Sanjay J Kshirsagar
Oral suspension is the most preferred dosage form for the paediatric population because of the difficulties related to solid medications, such as the swallowing limitations, bitter taste, and poor oral bioavailability, which can cause serious impairment to attain a successful treatment. Given the importance of successful therapies, there is a need for safe and effective commercially-available paediatric oral suspension and their characterization. For the latter, it is important to identify safe excipients and preservatives...
April 28, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38688060/development-and-translation-of-thiometallate-sulfide-donors-using-a-porcine-model-of-coronary-occlusion-and-reperfusion
#23
JOURNAL ARTICLE
Thomas W Johnson, James Holt, Anna Kleyman, Shengyu Zhou, Eva Sammut, Vito Domenico Bruno, Charlotte Gaupp, Giacomo Stanzani, John Martin, Pietro Arina, Julia Deutsch, Raimondo Ascione, Mervyn Singer, Alex Dyson
Sulfide-releasing compounds reduce reperfusion injury by decreasing mitochondria-derived reactive oxygen species production. We previously characterised ammonium tetrathiomolybdate (ATTM), a clinically used copper chelator, as a sulfide donor in rodents. Here we assessed translation to large mammals prior to clinical testing. In healthy pigs an intravenous ATTM dose escalation revealed a reproducible pharmacokinetic/pharmacodynamic (PK/PD) relationship with minimal adverse clinical or biochemical events. In a myocardial infarction (1-h occlusion of the left anterior descending coronary artery)-reperfusion model, intravenous ATTM or saline was commenced just prior to reperfusion...
April 25, 2024: Redox Biology
https://read.qxmd.com/read/38686848/comprehensive-review-of-tenecteplase-for-thrombolysis-in-acute-ischemic-stroke
#24
REVIEW
Liyuan Wang, Manjun Hao, Na Wu, Shuangzhe Wu, Marc Fisher, Yunyun Xiong
Although intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase. Animal studies have demonstrated the favorable pharmacokinetics and pharmacodynamics of tenecteplase. Moreover, it is easier to administer. Clinical trials have demonstrated that tenecteplase is not inferior to alteplase and may even be superior in cases of acute ischemic stroke with large vessel occlusion. Current evidence supports the time and cost benefits of tenecteplase, suggesting that it could potentially replace alteplase as the main option for thrombolytic therapy, especially in patients with large vessel occlusion...
April 30, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38686601/sound-exposure-promotes-intratympanic-drug-delivery-to-the-inner-ear
#25
JOURNAL ARTICLE
Omer J Ungar, Yumai Situ, Jennifer L Spiegel, Joseph M Chen, Vincent Y W Lin, Trung N Le
OBJECTIVE: To investigate the impact of sound exposure, with the resultant windows vibration on perilymphatic concentrations following intratympanic (IT) dexamethasone and gentamicin in an animal model. STUDY DESIGN: Animal model blinded study. SETTING: Animal facility of a tertiary medical center. METHODS: Bilateral IT dexamethasone or gentamicin was applied to 15 tested rats. Following injections, each rat was exposed for 3 minutes to free field 30 dB sound pressure level (SPL), 512 vHz noise, with 1 external auditory canal plugged (contralateral control)...
April 30, 2024: Otolaryngology—Head and Neck Surgery
https://read.qxmd.com/read/38686508/pharmacokinetic-pharmacodynamic-and-safety-profiles-of-proline-henagliflozin-in-chinese-subjects-with-varying-degrees-of-liver-dysfunction
#26
JOURNAL ARTICLE
Likun Ding, Lin Yang, Danjun Ren, Xiaohua Gao, Juanli Zhang, Meiyou Liu, Li Sun, Qingbo Diao, Sheng Feng, Aidong Wen, Jingwen Wang
Proline henagliflozin, a novel selective inhibitor of sodium glucose cotransporter 2, is a treatment for type 2 diabetes mellitus. We designed a parallel-group, open-label, and multicenter study to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of henagliflozin in Chinese subjects with varying degrees of liver dysfunction. Thirty-two subjects were enrolled and divided into four groups based on liver function (normal liver function, mild, moderate, or severe liver dysfunction). The area under the plasma concentration from time zero to infinity of henagliflozin in subjects with mild liver dysfunction, moderate liver dysfunction, and severe liver dysfunction compared with normal liver function was increased by 137%, 197%, and 204%, respectively...
April 30, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38686236/the-rise-of-remimazolam-a-review-of-pharmacology-clinical-efficacy-and-safety-profiles
#27
REVIEW
Saiesh Dessai, Sanjot Ninave, Amol Bele
Anesthesiologists often use benzodiazepines (BZDs) due to their remarkable amnestic and anxiolytic capabilities. Because of this, they are perfect for use during the perioperative phase, when patients' anxiety levels are already high. Remimazolam has replaced certain commonly used intravenous (IV) anesthetics due to its excellent safety profile, rapid onset of action, and short half-life. The four classes of BZDs, 2-keto-benzodiazepines, 3-hydroxy-benzodiazepines, triazolobenzodiazepines, and 7-nitro-benzodiazepines based on chemical structure, provide various levels of drowsiness, forgetfulness, and anxiolysis...
March 2024: Curēus
https://read.qxmd.com/read/38685682/lessons-learned-from-the-failure-of-solanezumab-as-a-prospective-treatment-strategy-for-alzheimer-s-disease
#28
JOURNAL ARTICLE
Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Roberta Stallone, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza
INTRODUCTION: In the last decade, the efforts conducted for discovering Alzheimer's Disease (AD) treatments targeting the best-known pathogenic factors [amyloid-β (Aβ), tau protein, and neuroinflammation] were mostly unsuccessful. Given that a systemic failure of Aβ clearance was supposed to primarily contribute to AD development and progression, disease-modifying therapies with anti-Aβ monoclonal antibodies (e.g. solanezumab, bapineuzumab, gantenerumab, aducanumab, lecanemab and donanemab) are ongoing in randomized clinical trials (RCTs) with contrasting results...
April 29, 2024: Expert Opinion on Drug Discovery
https://read.qxmd.com/read/38685143/medicinal-chemistry-strategies-toward-broad-spectrum-antiviral-agents-to-prevent-next-pandemics
#29
REVIEW
Zirui Lü, Xiandong Dai, Jianjie Xu, Zhenming Liu, Yongbiao Guo, Zhenhua Gao, Fanhua Meng
The pandemic and tremendous impact of severe acute respiratory syndrome coronavirus 2 alert us, despite great achievements in prevention and control of infectious diseases, we still lack universal and powerful antiviral strategies to rapidly respond to the potential threat of serious infectious disease. Various highly contagious and pathogenic viruses, as well as other unknown viruses may appear or reappear in human society at any time, causing a catastrophic epidemic. Developing broad-spectrum antiviral drugs with high security and efficiency is of great significance for timely meeting public health emergency and protecting the lives and health of the people...
April 25, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38684590/silk-fibroin-formed-bioadhesive-ophthalmic-gel-for-dry-eye-syndrome-treatment
#30
JOURNAL ARTICLE
Tianjiao Hao, Lu Tang, Qianzi Xu, Wei Wang, Zengjing Li, Yan Shen, Bohui Xu, Hao Luo, Qian Li, Jirong Wang, Jinling Zhang
PURPOSE: Dry eye syndrome (DES), arising from various etiologic factors, leads to tear film instability and ocular surface damage. Given its anti-inflammatory effects, cyclosporine A (CsA) has been widely used as a short-term treatment option for DES. However, poor bioavailability and solubility of CsA in aqueous phase make the development of a cyclosporine A-based eye drop for ocular topical application a huge challenge. METHODS: In this study, a novel strategy for preparing cyclosporine A-loaded silk fibroin nanoemulsion gel (CsA NBGs) was proposed to address these barriers...
April 29, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38684588/survey-of-data-package-and-sample-size-of-comparative-clinical-studies-for-biosimilar-developments-from-pmda-assessments
#31
JOURNAL ARTICLE
Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, Yasuhiro Kishioka
BACKGROUND: The Japanese biosimilar guideline requires that the sponsors conduct clinical studies such as comparative pharmacokinetic (PK), pharmacodynamic (PD), or efficacy studies. In each biosimilar development, the sponsors consider the clinical data package, and thus clinical data packages vary among biosimilar developments. OBJECTIVES: The aim of this study was to elucidate the clinical data packages for the biosimilars approved in Japan. The details of clinical data packages and sample size for the regulatory approvals of biosimilars in Japan was reported...
April 29, 2024: Pharmaceutical Medicine
https://read.qxmd.com/read/38683493/pb006-a-natalizumab-biosimilar
#32
REVIEW
Matt Shirley
PB006 (Tyruko® ) is the first biosimilar of the reference monoclonal anti-α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple sclerosis (RRMS). PB006 has similar physicochemical and pharmacodynamic properties to those of reference natalizumab, and the pharmacokinetic similarity of the agents has been demonstrated in a study in healthy subjects...
April 29, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38683032/predicting-the-outcome-in-poisoned-patients-look-at-the-past
#33
REVIEW
Samanta M Zwaag, Claudine C Hunault, Dylan W de Lange
INTRODUCTION: When predicting future events, we often rely on analyzing past occurrences and projecting them forward. This methodology is crucial in various fields, including toxicology, in which predicting outcomes in poisoned patients plays a vital role in guiding treatment decisions and improving patient care. IMPORTANCE OF PREDICTING OUTCOMES IN POISONED PATIENTS: In cases of poisoning, understanding a patient's medical history, current physiological status, and the toxicokinetics of the ingested substance is essential for predicting potential outcomes and determining appropriate interventions...
March 2024: Clinical Toxicology
https://read.qxmd.com/read/38682317/predicted-deleterious-variants-in-abca1-lpl-lpa-and-kif6-are-associated-with-statin-response-and-adverse-events-in-patients-with-familial-hypercholesterolemia-and-disturb-protein-structure-and-stability
#34
JOURNAL ARTICLE
Carolina Dagli-Hernandez, Glaucio Monteiro Ferreira, Renata Caroline Costa de Freitas, Jessica Bassani Borges, Victor Fernandes de Oliveira, Rodrigo Marques Gonçalves, Andre Arpad Faludi, Elisangela da Silva Rodrigues Marçal, Gisele Medeiros Bastos, Raul Hernandes Bortolin, Mario Hiroyuki Hirata, Rosario Dominguez Crespo Hirata
OBJECTIVES: This study explored the association of deleterious variants in pharmacodynamics (PD) genes with statin response and adverse effects in patients with familial hypercholesterolemia (FH) and analyzed their potential effects on protein structure and stability. METHODS: Clinical and laboratory data were obtained from 144 adult FH patients treated with statins. A panel of 32 PD genes was analyzed by exon-targeted gene sequencing. Deleterious variants were identified using prediction algorithms and their structural effects were analyzed by molecular modeling studies...
June 1, 2024: Pharmacogenetics and Genomics
https://read.qxmd.com/read/38682267/aticaprant-a-%C3%AE%C2%BA-opioid-receptor-antagonist-for-major-depressive-disorder
#35
REVIEW
Elliot Hampsey, Luke Jelen, Allan H Young
INTRODUCTION: Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide according to the WHO. Due to the imperfect efficacy and tolerability profiles of existing treatments, investigational compounds in novel treatment classes are needed. Opioid-receptor antagonists are a potential new class of treatments currently under investigation. AREAS COVERED: Major depressive disorder is first overviewed...
April 29, 2024: Expert Opinion on Emerging Drugs
https://read.qxmd.com/read/38681192/early-precise-and-safe-clinical-evaluation-of-the-pharmacodynamic-effects-of-novel-agents-in-the-intact-human-tumor-microenvironment
#36
JOURNAL ARTICLE
Kenneth R Gundle, Karthik Rajasekaran, Jeffrey Houlton, Gary B Deutsch, Thomas J Ow, Robert G Maki, John Pang, Cherie-Ann O Nathan, Daniel Clayburgh, Jason G Newman, Elyse Brinkmann, Michael J Wagner, Seth M Pollack, Matthew J Thompson, Ryan J Li, Vikas Mehta, Bradley A Schiff, Barry I Wenig, Paul L Swiecicki, Alice L Tang, Jessica L Davis, Annemieke van Zante, Jessica A Bertout, Wendy Jenkins, Atticus Turner, Marc Grenley, Connor Burns, Jason P Frazier, Angela Merrell, Kimberly H W Sottero, Jonathan M J Derry, Kate C Gillespie, Bre Mills, Richard A Klinghoffer
Introduction: Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as low as 6.7% for oncology drugs. Over half of these failures are due to a lack of drug efficacy. This pervasive and repeated low rate of success exemplifies how preclinical models fail to adequately replicate the complexity and heterogeneity of human cancer. Therefore, new methods of evaluation, early in the development trajectory, are essential both to rule-in and rule-out novel agents with more rigor and speed, but also to spare clinical trial patients from the potentially toxic sequelae (high risk) of testing investigational agents that have a low likelihood of producing a response (low benefit)...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38678002/development-of-novel-indole-quinoline-hybrid-molecules-targeting-bacterial-proton-motive-force
#37
JOURNAL ARTICLE
Jinbeom Seo, Ji-Hoon Kim, Nayoung Ko, Jihyeon Kim, Kyeongwon Moon, In Su Kim, Wonsik Lee
AIMS: This study aimed to develop an editable structural scaffold for improving drug development including pharmacokinetics and pharmacodynamics of antibiotics by using synthetic compounds derived from a (hetero)aryl-quinoline hybrid scaffold. METHODS AND RESULTS: In this study, 18 CF3-substituted (hetero)aryl-quinoline hybrid molecules were examined for their potential antibacterial activity against Staphylococcus aureus by determining minimal inhibitory concentrations...
April 27, 2024: Journal of Applied Microbiology
https://read.qxmd.com/read/38677803/building-a-pediatric-neurocritical-care-program-the-role-of-the-clinical-pharmacist-practitioner-on-clinical-practice-and-education-a-curriculum-for-neuropharmacology-training
#38
REVIEW
Jon A Cokley, Steven M Lazar
Clinical pharmacists are a part of the integrated health care team and provide valuable input on medication management for patients with acute and chronic disease states. Using epilepsy as a model, pharmacist involvement in patient care has been associated with significant reductions in monthly seizure frequency. Given differences in etiology, pediatric patients with epilepsy are likely to have higher number of treatments, with additional pharmacodynamic and pharmacokinetic differences, adding to the importance of utilizing a pediatric clinical pharmacist practitioner with neuropharmacology expertise...
April 2024: Seminars in Pediatric Neurology
https://read.qxmd.com/read/38677569/network-pharmacology-combined-with-affinity-ultrafiltration-to-elucidate-the-potential-compounds-of-shaoyao-gancao-fuzi-decoction-for-the-treatment-of-rheumatoid-arthritis
#39
JOURNAL ARTICLE
Weiliang Fu, Chengyu Shentu, Dan Chen, Junjie Qiu, Chuhong Zong, Hengyuan Yu, Yiwei Zhang, Yong Chen, Xuesong Liu, Tengfei Xu
ETHNOPHARMACOLOGICAL RELEVANCE: Shaoyao Gancao Fuzi Decoction (SGFD), has been employed for thousands of years in the treatment of rheumatoid arthritis (RA) with remarkable clinical efficacy. However, the material basis underlying the effectiveness of SGFD still remains unclear. AIM OF THE REVIEW: This study aims to elucidate the material basis of SGFD through the application of network pharmacology and biological affinity ultrafiltration. RESULTS: UPLC-Q-TOF-MS/MS was employed to characterize the components in SGFD, the identified 145 chemical components were mainly categorized into alkaloids, flavonoids, triterpenoids, and monoterpenoids according to the structures...
April 25, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38677300/temporal-changes-in-sars-cov-2-clearance-kinetics-and-the-optimal-design-of-antiviral-pharmacodynamic-studies-an-individual-patient-data-meta-analysis-of-a-randomised-controlled-adaptive-platform-study-platcov
#40
JOURNAL ARTICLE
Phrutsamon Wongnak, William H K Schilling, Podjanee Jittamala, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M Batty, Shivani Singh, Jindarat Kouhathong, Watcharee Pagornrat, Patpannee Khanthagan, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mayfong Mayxay, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Elizabeth A Ashley, Arjen M Dondorp, Nicholas P J Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, James A Watson
BACKGROUND: Effective antiviral drugs prevent hospitalisation and death from COVID-19. Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities quantitated in nasopharyngeal or oropharyngeal swab eluates. We conducted an individual patient data meta-analysis of unblinded arms in the PLATCOV platform trial to characterise changes in viral clearance kinetics and infer optimal design and interpretation of antiviral pharmacometric evaluations...
April 24, 2024: Lancet Infectious Diseases
keyword
keyword
6597
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.